Summary
Diabetes mellitus and hyperlipidemia are associated with coronary heart disease and with hypercoagulability, another independent risk factor for coronary heart disease. In 65 non-insulin-dependent diabetes mellitus patients [41 females, 24 males, median age 66 years (range 43–81 years)] treated with antidiabetic agents glycometabolic control (HbA1c), lipids (Quetelet index and blood lipids), and several coagulation parameters were studied in comparison with a reference group. Serum triglycerides were elevated [median (interquartile range) 2.3 (1.3) mmol/l vs. 1.6 (0.7) mmol/l in the controls (P<0.001)], whereas the median lipoprotein(a) concentration was 65 (157) mg/l in the diabetic patients versus 44 (114) mg/l in the control group (not significantly different). Median high-density lipoprotein-cholesterol concentrations were slightly decreased in the diabetic patients: 1.2 (0.3) mmol/l compared with 1.3 (0.4) mmol/l in the control group (P<0.02). Elevated levels of fibrinogen, fibrin monomers, thrombin-antithrombin III complex, and factor VIIIc were found in the diabetic patients and factor VII in male diabetic patients. These elevated coagulation parameters are indicators of an activated coagulation system in this patient group. By Spearman’s rank test, only HbA1c values correlated with antithrombin III (r=0.27,P<0.03) and showed a tendency towards a correlation with lipoprotein(a) (r=0.23,P<0.07). Triglycerides correlated with the Quetelet index (r=0.27,P<0.03), high-density lipoprotein-cholesterol (r=−0.41,P<0.001), and factor VII (r=0.35,P<0.01), whereas serum cholesterol concentrations correlated with factor VII (r=0.27,P<0.04) and with fibrin monomers (r=0.29,P<0.03). In this group of 65 non-insulin-dependent diabetes mellitus patients we found a characteristic adverse lipid profile in association with signs of an activated coagulation system. Glycometabolic control appeared to have no major influence on the degree of activation of the coagulation system in these patients. This study supports the more aggressive approach advised in the treatment of hyperlipidemia in diabetic patients.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
American Diabetes Association, Role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes. Diabetes Care 12:573, 1989
Brownlee M, Cerami A, Vlassara H, Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 318:1315, 1988
Bruckert E, Davidoff P, Grimaldi A, Truffert J, Giral P, Doumith R, Thervet F, De Gennes JL, Increased serum levels of lipoprotein(a) in diabetes mellitus and their reduction with glycemic control. JAMA 263:35, 1990
Brunzell JD, Porte D Jr, Bierman EL, Abnormal lipoprotein lipase mediated plasma triglyceride removal in untreated diabetes mellitus associated with hypertriglyceridemia. Metabolism 28:901, 1979
Carvalho de Sousa J, Bruckert E, Giral P, Soria C, Chapman J, Truffert J, Dairou F, De Gennes JL, Caen JP, Coagulation factor VII and plasma triglycerides. Descreased catabolism as a possible mechanism of factor VII hyperactivity. Haemostasis 19:125, 1989
Ceriello A, Dello Russo P, Zucotti C, Florio A, Nazarro S, Pietrantuono C, Rosato GB, Decreased antithrombin III activity in diabetes may be due to non-enzymatic glycosylation. Thromb Haemost 46:648, 1981
Ceriello A, Giugliano D, Quatraro A, Stante A, Dello Russo P, Torella R, Increased alpha 2-macroglobulin in diabetes: a hyperglycemia related phenomenon associated with reduced antithrombin III activity. Acta Diabetol Lat 26:147, 1989
Ceriello A, Giugliano D, Quatraro A, Marchi E, Barbanti M, Lefebvre P, Evidence for a hyperglycaemia-dependent decrease of antithrombin III thrombin complex formation in humans. Diabetologia 33:163, 1990
Chakrabarti R, Hocking ED, Fearnley GR, Mann RD, Attwell TN, Jackson D, Fibrinolytic activity and coronary-artery disease. Lancet I:987, 1968
Christe M, Fritschi J, Lämmle B, Tran TH, Marbet GA, Berger W, Duckert F, Fifteen coagulation and fibrinolysis parameters in diabetes mellitus and in patients with vasculopathy. Thromb Haemost 52:138, 1984
Constantino M, Merskey L, Kudzma DJ, Zucker MB, Increased activity of vitamin K-dependent clotting factors in human hyperlipoproteinaemia-association with cholesterol and triglyceride levels. Thromb Haemost 38:465, 1977
Dalaker K, Hjermann I, Prydz H, A novel form of factor VII in plasma from men at risk for cardiovascular disease. Br J Haematol 61:315, 1985
DeFronzo RA, Lilly Lecture 1987. The triumvirate: β cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 37:667, 1988.
Dornan TL, Carter RD, Bron AJ, Turner RC, Mann JI, Low density lipoprotein cholesterol: an association with the severity of diabetic retinopathy. Diabetologia 22:167, 1982
Ernst E, Plasma fibrinogen, an independent cardiovascular risk factor. J Intern Med 227:365, 1990
Fontbonne A, Eschwege E, Cambien F, Richard JL, Ducimetiere P, Thibult N, Warnet JM, Claude JR, Rosselin GE, Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Diabetologia 32:300, 1989
Fuller JH, Keen H, Jarrett RJ, Omer T, Meade TW, Chakrabarti R, North WR, Stirling Y, Haemostatic variables associated with diabetes its complications. BMJ 2:964, 1979
Geiger M, Binder BR, Plasminogen activation in diabetes mellitus. Kinetic analysis of plasmin formation using components isolated from the plasma of diabetic donors. J Biol Chem 259:2976, 1984
Geiger M, Binder BR, Non-enzymatic glycosylation as a contributing factor to defective fibrinolysis in diabetes mellitus. Haemostasis 16:439, 1986
Grignani G, Gamba G, Geroldi D, Pacchiarini L, Solerte B, Ferrari E, Ascari E, Enhanced antithrombotic mechanisms in patients with maturity onset diabetes mellitus without thromboembolic complications. Thromb Haemost 46:648, 1981
Haffner SM, Fong D, Hazuda HP, Pugh JA, Patterson JK, Hyperinsulinemia, upper body adiposity, and cardiovascular risk factors in non-diabetics. Metabolism 37:338, 1988
Haffner SM, Tuttle KR, Rainwater DL, Decrease of lipoprotein(a) with improved glycemic control in IDDM subjects. Diabetes Care 14:302, 1991
Hamsten A, Wiman B, Faire U de, Blombäck M, Increased plasma levels of rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 313:1557, 1985
Ikeda T, Ochi H, Ohtani I, Fujiyama K, Hoshino T, Tanaka Y, Takeuchi T, Mashiba H, Serum lipid and apolipoprotein levels in non-hypertensive lean NIDDM patients. J Intern Med 230:131, 1991
Kapelrud H, Bangstad H-J, Dahl-Jørgensen K, Berg K, Hanssen KF, Serum Lp(a) lipoprotein concentrations in insulin dependent diabetic patients with microalbuminuria. BMJ 303:675, 1991
Kissebah AH, Adams PW, Wynn V, Interrelationship between insulin secretion and plasma free fatty acid and triglyceride transport kinetics in maturity onset diabetes and the effect of phenethylbiguanide (Phenformin). Diabetologia 10:119, 1974
Krone W, Nägele H, Effects of antihypertensives on plasma lipids and lipoprotein metabolism. Am Heart J 116:1729, 1988
Levitsky LL, Scanu AM, Gould SH, Lipoprotein(a) levels in black and white children and adolescents with IDDM. Diabetes Care 14:283, 1991
Lütjens A, Jonkhoff-Slok TW, Sandkuijl C, Veen EA vd, Meer J vd. Polymerisation and crosslinking of fibrin monomers in diabetes mellitus. Diabetologia 31:825, 1988
Marongiu F, Conti M, Mameli G, Sorano GG, Cossu E, Cirillo R, Balestrieri A, Is the imbalance between thrombin and plasmin activity in diabetes related to the behaviour of antiplasmin activity? Thromb Res 58:91, 1990
Meade TW, North WR, Chakrabarti R, Stirling Y, Haines AP, Thompson SG, Brozovic M, Haemostatic function and cardiovascular death: early results of a prospective study. Lancet 1: 1050, 1980
Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet II:533, 1986
Mirshahi M, Soria J, Soria C, Bertrand O, Mirshahi M, Basdevant A, Glycosylation of human fibrinogen and fibrin in vitro. Its consequences on the properties of fibrin(ogen). Thromb Res 48:279, 1987
Nordøy A, Illingworth DR, Connor WE, Goodnight S Jr, Increased activity of factor VII and factor VII-phospholipid complex measured using a Normotest system in subjects with hyperlipidemia. Haemostasis 20:65, 1990
Orchard TJ, Becker DJ, Bates M, Kuller LH, Drash AL, Plasma insulin and lipoprotein concentrations: an atherogenic association? Am J Epidemiol 118:326, 1983
Ostermann H, Loo J van de, Factors of the hemostatic system in diabetic patients. A survey of controlled studies. Haemostasis 16:386, 1986
Paterson JR, Pettigrew AR, Dominiczak MH, Small M, Screening for hyperlipidaemia in diabetes mellitus. Relationship to glycaemia control. Ann Clin Biochem 28:354, 1991
Pyorala K, Laakso M, Uusitupa M, Diabetes and atherosclerosclerosis: an epidemiologic view. Diabetes Metab Rev 3:463, 1987
Reaven GM, Non-insulin-dependent diabetes mellitus, abnormal lipoprotein metabolism, and atherosclerosis. Metabolism 36 [Suppl 1]:1, 1987
Reaven GM, Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37:1595, 1988
Rosengren A, Welin L, Tsipogianni A, Wilhelmsen L, Impact of cardiovascular risk factors on coronary heart disease and mortality among middle aged diabetic men: a general population study. BMJ 299:1127, 1989
Simpson HC, Mann JI, Meade TW, Chakrabarti R, Stirling Y, Woolf L, Hypertriglyceridaemia and hypercoagulability. Lancet I:786, 1983
Small M, Kluft C, MacCuish AC, Lowe GD, Tissue plasminogen activator inhibiton in diabetes mellitus. Diabetes Care 12:655, 1989
Sowers JR, Tuck ML, Sowers DK, Plasma antithrombin III and thrombin generation time: correlation with hemoglobin A1 and fasting serum glucose in young diabetic women. Diabetes Care 3:655, 1980
Trip MD, Cats VM, Capelle FJ van, Vreeken J, Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med 322:1549, 1990
Tschoepe D, Ostermann H, Huebinger A, Ziegler D, Wiefels K, Gries FA, Elevated platelet activation in type I diabetics with chronic complications under long-term near-normoglycemic control. Haemostasis 20:93, 1990
Zavaroni I, Bonora E, Pagliara M, Dall’Aglio E, Luchetti L, Buonanno G, Bonati PA, Bergonzani M, Gnudi L, Passeri M, Reaven G, Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. N Engl J Med 320:702, 1989
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Donders, S.H.J., Lustermans, F.A.T. & van Wersch, J.W.J. Glycometabolic control, lipids, and coagulation parameters in patients with non-insulin-dependent diabetes mellitus. Int J Clin Lab Res 23, 155–159 (1993). https://doi.org/10.1007/BF02592301
Issue Date:
DOI: https://doi.org/10.1007/BF02592301